SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Zwart J. A.)
 

Search: WFRF:(Zwart J. A.) > (2010-2014) > PKA-induced phospho...

  • Kok, MarleenNetherlands Cancer Institute (author)

PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2010-03-09
  • Springer Science and Business Media LLC,2011

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:50be076f-13c6-46b2-bef1-aebd30836411
  • https://lup.lub.lu.se/record/1774207URI
  • https://doi.org/10.1007/s10549-010-0798-yDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-63953URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Phosphorylation of estrogen receptor alpha at serine 305 (ER alpha S305-P) by protein kinase A (PKA) or p21-activated kinase 1 (PAK1) has experimentally been associated with tamoxifen sensitivity. Here, we investigated the clinical application of this knowledge to predict tamoxifen resistance in ER-positive breast cancer patients. Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER alpha S305-P (PKA/ER alpha S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment. In the training set, PAK1 levels were associated with tumor progression after tamoxifen (HR 1.57, 95% CI 0.99-2.48), as was co-expression of PKA and ER alpha S305-P (HR 2.00, 95% CI 1.14-3.52). In the validation set, a significant tamoxifen benefit was found among the 73% patients negative for PAK1 and PKA/ER alpha S305-P (HR 0.54, 95% CI 0.34-0.87), while others (27%) were likely to have no benefit from tamoxifen (HR 0.88, 95% 0.42-1.82). The test for interaction showed a significant difference in recurrence-free survival between groups defined by PAK1 and PKA/ER alpha S305-P (P = 0.037). Elevated PAK1 and PKA/ER alpha S305-P appeared to influence tamoxifen sensitivity. Both PAK1 and PKA/ER alpha S305-P levels were associated with sensitivity to tamoxifen in breast tumors and the combination of these variables should be considered in predicting tamoxifen benefit.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Zwart, WilbertNetherlands Cancer Institute (author)
  • Wigerup, CarolineLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups(Swepub:lu)pat-cho (author)
  • Fles, RenskeNetherlands Cancer Institute (author)
  • Hauptmann, MichaelNetherlands Cancer Institute (author)
  • Van't Veer, Laura J.Netherlands Cancer Institute (author)
  • Wessels, Lodewyk F. A.Netherlands Cancer Institute (author)
  • Neefjes, JacquesNetherlands Cancer Institute (author)
  • Stål, OlleÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)ollst87 (author)
  • Linn, Sabine C.Netherlands Cancer Institute (author)
  • Landberg, GöranLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups(Swepub:lu)pat-gla (author)
  • Michalides, RobNetherlands Cancer Institute (author)
  • Holm, CarolineLund University (author)
  • Netherlands Cancer InstitutePatologi, Malmö (creator_code:org_t)

Related titles

  • In:Breast Cancer Research and Treatment: Springer Science and Business Media LLC125:1, s. 1-121573-72170167-6806

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view